| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 377 |
| Referral date | 01 June 2010 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 15 February 2013 |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | Andrew Dillon |
| Project manager: | Kate Moore |
| Technical Lead: | Grace Jennings |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in October 2009, the appraisal of Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in October 2009, the appraisal of Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 May 2013 |
NICE has been informed by the sponsor, Arena Pharmaceuticals, that they have withdrawn their licensing application for the above indication. The company is currently evaluating the best approach for submitting at a later date. Therefore this topic has now been suspended. We will continue to monitor any development and update you if the situation changes. |
| 03 May 2013 |
Following an update on the regulatory status of this technology from the manufacturer, the discussion of this appraisal at the Committee meeting on 30 May 2013 has been cancelled. We will update you with more information in due course. |
| 23 July 2012 |
Following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early December 2012. The deadline for submissions is expected in approximately mid February 2013. |
| 02 November 2011 |
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid October 2012. The deadline for submissions is expected in approximately mid December 2012. |
For further information on our processes and methods, please see our CHTE processes and methods manual